Trial Profile

Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled, Safety, Tolerability, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Phase Ib/IIa Clinical Trial With AC01 in Patients With HFrEF

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Apr 2024 Planned End Date changed from 1 Nov 2024 to 30 Jun 2025.
24 Apr 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
26 Apr 2023 According to a Helsinn media release, this trial has received approval from the Competent Authorities and Ethics committees in Sweden, the Netherlands, Italy and the UK.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com